Literature DB >> 34902076

Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management.

Tyger Lin1, Rose A Gubitosi-Klug2, Roomasa Channa3, Risa M Wolf4.   

Abstract

PURPOSE OF REVIEW: Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and a major cause of vision loss worldwide. The purpose of this review is to provide an update on the prevalence of diabetic retinopathy in youth, discuss risk factors, and review recent advances in diabetic retinopathy screening. RECENT
FINDINGS: While DR has long been considered a microvascular complication, recent data suggests that retinal neurodegeneration may precede the vascular changes associated with DR. The prevalence of DR has decreased in type 1 diabetes (T1D) patients following the results of the Diabetes Control and Complications Trial and implementation of intensive insulin therapy, with prevalence ranging from 14-20% before the year 2000 to 3.7-6% after 2000. In contrast, the prevalence of diabetic retinopathy in pediatric type 2 diabetes (T2D) is higher, ranging from 9.1-50%. Risk factors for diabetic retinopathy are well established and include glycemic control, diabetes duration, hypertension, and hyperlipidemia, whereas diabetes technology use including insulin pumps and continuous glucose monitors has been shown to have protective effects. Screening for DR is recommended for youth with T1D once they are aged ≥ 11 years or puberty has started and diabetes duration of 3-5 years. Pediatric T2D patients are advised to undergo screening at or soon after diagnosis, and annually thereafter, due to the insidious nature of T2D. Recent advances in DR screening methods including point of care and artificial intelligence technology have increased access to DR screening, while being cost-saving to patients and cost-effective to healthcare systems. While the prevalence of diabetic retinopathy in youth with T1D has been declining over the last few decades, there has been a significant increase in the prevalence of DR in youth with T2D. Improving access to diabetic retinopathy screening using novel screening methods may help improve detection and early treatment of diabetic retinopathy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Artificial intelligence; Diabetic retinopathy; Pediatric diabetes; Protective factors; Risk factors; Type 1 diabetes; Type 2 diabetes

Mesh:

Year:  2021        PMID: 34902076     DOI: 10.1007/s11892-021-01436-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  95 in total

1.  Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

Authors:  N H White; P A Cleary; W Dahms; D Goldstein; J Malone; W V Tamborlane
Journal:  J Pediatr       Date:  2001-12       Impact factor: 4.406

2.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.

Authors:  Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2019-01-18       Impact factor: 6.118

3.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

Review 4.  Aldose reductase in diabetic microvascular complications.

Authors:  S S M Chung; S K Chung
Journal:  Curr Drug Targets       Date:  2005-06       Impact factor: 3.465

5.  Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study.

Authors:  B Muñoz; S K West; G S Rubin; O D Schein; H A Quigley; S B Bressler; K Bandeen-Roche
Journal:  Arch Ophthalmol       Date:  2000-06

Review 6.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism.

Authors:  Krysten M Farjo; Rafal A Farjo; Stacey Halsey; Gennadiy Moiseyev; Jian-Xing Ma
Journal:  Mol Cell Biol       Date:  2012-10-15       Impact factor: 4.272

Review 8.  Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.

Authors:  Rachelle Gandica; Phil Zeitler
Journal:  Adv Pediatr       Date:  2016-06-03

9.  Montelukast Prevents Early Diabetic Retinopathy in Mice.

Authors:  Reena Bapputty; Ramaprasad Talahalli; Simona Zarini; Ivy Samuels; Robert Murphy; Rose Gubitosi-Klug
Journal:  Diabetes       Date:  2019-07-26       Impact factor: 9.461

Review 10.  The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.

Authors:  Mara Lorenzi
Journal:  Exp Diabetes Res       Date:  2007
View more
  1 in total

1.  Association between red blood cell distribution width-to-albumin ratio and diabetic retinopathy.

Authors:  Fengping Zhao; MengYun Liu; Lingzhen Kong
Journal:  J Clin Lab Anal       Date:  2022-03-13       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.